» Articles » PMID: 32086878

Changes in Kidney Function Among Men Having Sex with Men Starting on Demand Tenofovir Disoproxil Fumarate - Emtricitabine for HIV Pre-exposure Prophylaxis

Overview
Journal J Int AIDS Soc
Date 2020 Feb 23
PMID 32086878
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on-demand PrEP with TDF/FTC in HIV-1 uninfected men.

Methods: We used data from the randomized double-blind placebo-controlled ANRS-IPERGAY trial and its open-label extension conducted between February 2012 and June 2016 among HIV-uninfected MSM starting on-demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study.

Results: During the blind phase, with a median follow-up of 9.4 months, the mean decline slope of eGFR from baseline was -0.88 and -1.53 mL/min/1.73 m per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m per year (p = 0.27). Including both phases, 389 participants started on-demand TDF/FTC with a median follow-up of 19.2 months and a mean decline of eGFR from baseline of -1.14 mL/min/1.73 m per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR ≤ 90 mL/min/1.73 m (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose-response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of -0.88 mL/min/1.73 m between >15 pills/month vs. ≤15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to ≤2 ng/mL: >2 to ≤10ng/mL: -0.98 mL/min/1.73 m , >10 to ≤40ng/mL: -1.28 mL/min/1.73 m , >40 ng/mL: -1.82 mL/min/1.73 m , p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m during the OLE phase. No case of Fanconi syndrome was reported.

Conclusions: The renal safety of on-demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety.

Citing Articles

Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain.

Perez-Gonzalez A, Represa M, Coll P, Potel C, Rodriguez-Rivero S, Flores E Front Public Health. 2022; 10:1005622.

PMID: 36388349 PMC: 9650222. DOI: 10.3389/fpubh.2022.1005622.


Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.

Schaefer R, da Costa Leite P, Silva R, Abdool Karim Q, Akolo C, Caceres C Lancet HIV. 2022; 9(4):e242-e253.

PMID: 35271825 PMC: 8964504. DOI: 10.1016/S2352-3018(22)00004-2.


Delayed presentation of HIV among older individuals: a growing problem.

Justice A, Goetz M, Stewart C, Hogan B, Humes E, Luz P Lancet HIV. 2022; 9(4):e269-e280.

PMID: 35218732 PMC: 9128643. DOI: 10.1016/S2352-3018(22)00003-0.


Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.

Petruccelli K, Baia-da-Silva D, Val F, Valoes M, Cubas-Vega N, Silva-Neto A AIDS Res Ther. 2022; 19(1):12.

PMID: 35209929 PMC: 8867642. DOI: 10.1186/s12981-022-00437-4.


Complex PrEP: the factors requiring consultant-led review of PrEP users.

Tittle V, Dalton R, Nugent D, Girometti N, Whitlock G, Mcowan A Sex Transm Infect. 2022; 98(8):595-598.

PMID: 35169002 PMC: 9685731. DOI: 10.1136/sextrans-2021-055277.


References
1.
Saag M, Benson C, Gandhi R, Hoy J, Landovitz R, Mugavero M . Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018; 320(4):379-396. PMC: 6415748. DOI: 10.1001/jama.2018.8431. View

2.
Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I . Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis. J Int AIDS Soc. 2020; 23(2):e25420. PMC: 7035456. DOI: 10.1002/jia2.25420. View

3.
Jotwani V, Scherzer R, Glidden D, Mehrotra M, Defechereux P, Liu A . Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. J Acquir Immune Defic Syndr. 2018; 78(2):169-174. PMC: 6071417. DOI: 10.1097/QAI.0000000000001654. View

4.
Marcus J, Hurley L, Hare C, Nguyen D, Phengrasamy T, Silverberg M . Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016; 73(5):540-546. PMC: 5424697. DOI: 10.1097/QAI.0000000000001129. View

5.
Mugwanya K, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A . Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016; 71(4):374-80. PMC: 4770857. DOI: 10.1097/QAI.0000000000000868. View